Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin MacKey

Physician Assistant, Medical Beverly, MA Physician Assistant

NPI 1003992629 CMS profile 1160728

77 Herrick St, Suite 201 Coastal Orthopedic Associates, Beverly, MA 01915

Open in the dashboard

General payments

$3,838

124 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin MacKey of Beverly, MA is reported in the CMS Open Payments database as having received $3,838 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,559 73
2024 General $1,118 30
2023 General $928 15
2022 General $187 4
2021 General $47 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin MacKey
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Erin MacKey were reported at $1,559. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Erin MacKey Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $47 $156 $41–$563 $132
2022 $187 $185 $55–$649 $149
2023 $928 $199 $58–$717 $160
2024 $1,118 $206 $62–$740 $164
2025 $1,559 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,075 20 payments
  2. AbbVie, Inc. $924 40 payments
  3. UCB, Inc. $322 6 payments
  4. Galderma Laboratories, L.P. $237 16 payments
  5. Regeneron Healthcare Solutions, Inc. $190 4 payments
  6. E.R. Squibb & Sons, L.L.C. $185 4 payments
  7. Ferring Pharmaceuticals Inc. $147 1 payment
  8. Sun Pharmaceutical Industries Inc. $145 5 payments
  9. Janssen Scientific Affairs, LLC $114 1 payment
  10. Organon LLC $99 9 payments
  11. Other $399 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,486 120 payments
  2. Education $352 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,159 20 payments
  2. RINVOQ $417 11 payments
  3. SKYRIZI Immunology $360 23 payments
  4. Bimzelx $322 6 payments
  5. SKYRIZI Immunology $233 9 payments
  6. NEMLUVIO $195 14 payments
  7. SOTYKTU $185 4 payments
  8. REBYOTA $147 1 payment
  9. DUPIXENT $112 2 payments
  10. Winlevi $104 4 payments
  11. Other $918 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

244

Median for Physician Assistant: 241

Drug cost

$133,860

Median for Physician Assistant: $4,110

Branded share of claims

28.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 32 $127,105
Tacrolimus Generic 28 $3,077
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 38 $1,267
Clindamycin Phosphate Generic 18 $784
Ketoconazole Generic 43 $584
Triamcinolone Acetonide Generic 50 $539
Mometasone Furoate Generic 12 $237
Nystatin Generic 11 $146
Hydroxyzine Hcl Generic 12 $121

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $456
$456 — —
Bimzelx
  • UCB, Inc. $158
$158 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $136
$136 — —
SKYRIZI
  • AbbVie, Inc. $82
$82 — —
HADLIMA
  • Organon LLC $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record